StockWatch
·
Q2 FY-2027 RESULTS · KPL

Kwality Pharma Q2FY27: consol PAT doubles YoY to ₹29 Cr, margins expand, guidance raised

PAT +105.6% YoY · revenue +63.2% · margins expanding

Q2 FY27 resultsKPLKwality Pharmaceuticals Ltd12 Nov 2026 · 3 min read
Revenue

₹181.22 Cr

+63.2% YoY

PAT (consolidated)

₹29.03 Cr

+105.6% YoY

Net margin

15.95%

+3.3pp YoY

EPS

₹27.93

Kwality Pharmaceuticals' consolidated revenue grew 63.2% YoY to ₹181.2 Cr in Q2 FY27 (up 11.6% QoQ from ₹162.4 Cr in Q1 FY27), while consolidated PAT more than doubled YoY — up 105.6% to ₹29.03 Cr from ₹14.12 Cr a year ago, and up 13.3% sequentially from ₹25.62 Cr. Basic EPS rose to ₹27.93 from ₹13.60 a year earlier. There were no exceptional items in either the current or year-ago quarter, so this is organic growth, not a one-off-driven print. Notably, the company's own MD&A states PAT "doubled to ₹50 crore from ₹25 crore," but that figure does not tie to the board-approved, auditor-reviewed P&L (consolidated PAT ₹29.03 Cr, standalone ₹29.02 Cr); ₹50.6 Cr instead matches this quarter's EBITDA (PBT + finance cost + depreciation), so the press language appears to have conflated the two — the filed statement, not the prose, is the number of record.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹181.22 Cr+11.6%+63.2%
Expenses₹139.78 Cr+8.4%+49.5%
PAT₹29.03 Cr+13.3%+105.6%
Net margin15.95%+0.2pp+3.3pp
EPS₹27.93+13.1%+105.4%

Net profit margin expanded to 16.0% from 12.6% a year ago and 15.7% last quarter, and EBITDA margin rose to roughly 27.8% (on total income) from about 23.4% in Q2 FY26, which management attributes to operating leverage and a richer product mix as cost of materials consumed eased as a share of revenue. Finance costs were roughly flat YoY (₹2.99 Cr vs ₹2.84 Cr) even as total borrowings rose to ₹146 Cr from ₹130 Cr at FY26-end, while depreciation grew in line with continuing capex.

₹
3,015.543,321.823,628.13,934.384,240.664,122.108-1009-0109-2410-1911-1111-12Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹4,122.1, up 16.7% over the past month of trading.

₹ Cr
010.8421.6832.5111.92Q1 FY26rev ₹111 Cr14.12Q2 FY26rev ₹111 Cr16.01Q3 FY26rev ₹123 Cr25.29Q4 FY26rev ₹157 Cr25.62Q1 FY27rev ₹162 Cr29.03Q2 FY27rev ₹181 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
FY27 revenue ₹700+ Cr (reaffirmed from ₹650-700 range), EBITDA margins 26-27% unchanged. FY28-30 ambition: ₹1,500 Cr by FY30; hormone ₹150-200 Cr, biologics ₹200-250 Cr, oncology/generics sustained growth.

— This quarter: beat

Management raised FY27 revenue guidance to ₹720 Cr+ from the ₹700 Cr+ it had just reaffirmed last quarter (originally ₹650-700 Cr), while holding its EBITDA margin guidance at 26-27% — consistent with the quarter's delivered margin. H1FY27 consolidated revenue stands at ₹343.6 Cr, meaning H2 needs to average roughly ₹188 Cr a quarter to clear the new bar. There is no sell-side analyst coverage of the stock (zero analysts tracking it per AlphaSpread), so there is no street consensus to grade this print against. During the quarter the company received EU-GMP certification from Hungary for its Cephalosporin and Oncology manufacturing facilities, acquired 4 acres adjacent to its Amritsar campus to build "Unit 7" (envisaged with 4+ injectable and 6+ oral-solid-dosage lines), and completed bioequivalence studies for 19 products now ready for international regulatory filings — all cited by management as the basis for the guidance upgrade. Working capital discipline also improved, with the cash conversion cycle down to 130 days from 170 days in FY26.

  • W1

    H2FY27 revenue needs to average ~₹188 Cr/quarter (vs ₹181 Cr in Q2) to clear the raised ₹720 Cr+ FY27 guidance off a ₹343.6 Cr H1 base

  • W2

    EBITDA margin sustainability at 26-27% guided vs ~27.8% delivered in Q2, as Unit 7 capex begins

  • W3

    Oncology manufacturing expansion completion targeted June 2027; Hormone facility licence audit now underway after construction completion

Informational and educational content only. Not investment advice.